All Relations between dopaminergic and Substantia nigra

Publication Sentence Publish Date Extraction Date Species
Bushra Bashir, Shahbaz Alam, Nikhil Khandale, Devendra Birla, Sukriti Vishwas, Narendra Kumar Pandey, Gaurav Gupta, Keshav Raj Paudel, Harish Dureja, Puneet Kumar, Thakur Gurjeet Singh, Gowthamarajan Kuppusamy, Flavia Zacconi, Terezinha de Jesus Andreoli Pinto, Muralikrishnan Dhanasekaran, Monica Gulati, Kamal Dua, Sachin Kumar Sing. Opening avenues for treatment of neurodegenerative disease using post-biotics: Breakthroughs and bottlenecks in clinical translation. Ageing research reviews. 2024-02-18. PMID:38369026. post-biotic is believed to mediate its neuroprotection by elevating the level of dopamine and reducing the level of α-synuclein in substantia nigra, protecting the loss of dopaminergic neurons, reducing the aggregation of nft, reducing the deposition of amyloid β peptide plagues and ameliorating motor deficits. 2024-02-18 2024-02-21 human
Qing He, Shuzhen Zhang, Jian Wang, Tengfei Ma, Ding Ma, Li Wu, Mengxi Zhou, Lei Zhao, Yajing Chen, Jianren Liu, Wei Che. The Synergistic Effect Study of Lipopolysaccharide (LPS) and A53T-α-Synuclein: Intranasal LPS Exposure on the A53T-α-Synuclein Transgenic Mouse Model of Parkinson's Disease. Molecular neurobiology. 2024-02-17. PMID:38367134. according to our results, after intranasal administration of lps, a53t-α-syn mice showed severe progressive anosmia, hypokinesia, selective dopaminergic (daergic) neuronal losses, decreased striatal dopamine (da) level, and enhanced α-synuclein accumulation within the substantia nigra (sn) in an age-dependent way. 2024-02-17 2024-02-20 mouse
Areej Turkistani, Hayder M Al-Kuraishy, Ali I Al-Gareeb, Ali K Albuhadily, Athanasios Alexiou, Marios Papadakis, Mohamed M Elfiky, Hebatallah M Saad, Gaber El-Saber Batih. Therapeutic Potential Effect of Glycogen Synthase Kinase 3 Beta (GSK-3β) Inhibitors in Parkinson Disease: Exploring an Overlooked Avenue. Molecular neurobiology. 2024-02-17. PMID:38367137. parkinson's disease (pd) is a progressive neurodegenerative disease of the brain due to degeneration of dopaminergic neurons in the substantia nigra (sn). 2024-02-17 2024-02-20 Not clear
Audrey A Omidsalar, Carmel G McCullough, Lili Xu, Stanley Boedijono, Daniel Gerke, Michelle G Webb, Zarko Manojlovic, Adolfo Sequeira, Mark F Lew, Marco Santorelli, Geidy E Serrano, Thomas G Beach, Agenor Limon, Marquis P Vawter, Brooke E Hjel. Common mitochondrial deletions in RNA-Seq: evaluation of bulk, single-cell, and spatial transcriptomic datasets. Communications biology. vol 7. issue 1. 2024-02-17. PMID:38368460. a robust evaluation of 1570 samples from 14 rna-seq studies showed: (i) the abundance of some common deletions detected in pcr-amplified mtdna correlates with levels observed in rna-seq data; (ii) rna-seq library preparation method has a strong effect on deletion detection; (iii) deletions had a significant, positive correlation with age in brain and muscle; (iv) deletions were enriched in cortical grey matter, specifically in layers 3 and 5; and (v) brain regions with dopaminergic neurons (i.e., substantia nigra, ventral tegmental area, and caudate nucleus) had remarkable enrichment of common mtdna deletions. 2024-02-17 2024-02-20 human
Chayan Banerjee, Raju Barman, Priya Darshani, Meghana Pillai, Sanchi Ahuja, Rupsha Mondal, V S Pragadheesh, Joy Chakraborty, Deepak Kuma. α-Viniferin, a dietary phytochemical, inhibits monoamine oxidase and alleviates Parkinson's disease-associated behavioral deficits in a mice model. Neurochemistry international. 2024-02-16. PMID:38364939. behavioral complexities worsen over time due to progressive dopaminergic (dargic) neuronal loss at substantia nigra region of brain. 2024-02-16 2024-02-19 mouse
Pinky D Israni, Vaishnavi Yadav, Anam R Sasu. Effectiveness of Neurorehabilitation in Improving the Functional Recovery and Quality of Life of Patients With Parkinson's Disease: A Case Report. Cureus. vol 16. issue 1. 2024-02-13. PMID:38344634. key neuropathological findings include lewy bodies containing synuclein and the loss of dopaminergic neurons in the substantia nigra, reducing the facilitation of voluntary movements. 2024-02-13 2024-02-15 Not clear
David Zarate-Lopez, Andrea P Garzón-Partida, Oscar Gonzalez-Perez, Alma Y Gálvez-Contrera. Sex differences in autism-like behavior and dopaminergic neurons in substantia nigra of juvenile mice prenatally exposed to valproate. Developmental psychobiology. vol 66. issue 2. 2024-02-13. PMID:38351305. sex differences in autism-like behavior and dopaminergic neurons in substantia nigra of juvenile mice prenatally exposed to valproate. 2024-02-13 2024-02-16 mouse
Eun Jung Lee, David Hernán Aguirre-Padilla, Anton Fomenko, Grishma Pawar, Minesh Kapadia, Jimmy George, Andres M Lozano, Clement Hamani, Lorraine V Kalia, Suneil K Kali. Reduction of alpha synuclein oligomers in preclinical models of Parkinson's disease by electrical stimulation in vitro and deep brain stimulation in vivo. Brain stimulation. 2024-02-11. PMID:38342364. accumulation and oligomerization of the protein alpha-synuclein (α-syn) are implicated in the loss of dopaminergic neurons in the substantia nigra in pd, making α-syn a potential therapeutic target for disease modification. 2024-02-11 2024-02-14 Not clear
Fabio Casciano, Enrico Zauli, Claudio Celeghini, Lorenzo Caruso, Arianna Gonelli, Giorgio Zauli, Angela Pignatell. Retinal Alterations Predict Early Prodromal Signs of Neurodegenerative Disease. International journal of molecular sciences. vol 25. issue 3. 2024-02-10. PMID:38338966. in parkinson's disease, α-synuclein deposition in the retinal cells, as well as in dopaminergic neurons of the substantia nigra, alters the visual cortex and retinal function, resulting in modifications to the visual field. 2024-02-10 2024-02-12 Not clear
Takeya Kitta, Teruyuki Ogawa, Sadako Kuno, Hidehiro Kakizaki, Naoki Yoshimur. Review: Lower urinary tract dysfunction in animal models of Parkinson's disease (PD): Translational aspects for the treatment of PD patients with overactive bladder. International review of neurobiology. vol 174. 2024-02-10. PMID:38341230. although the loss of dopaminergic neurons in the substantia nigra and consequent motor symptoms are the hallmarks of parkinson's disease (pd), several non-motor symptoms may appear prior to these typical motor symptoms. 2024-02-10 2024-02-14 Not clear
Shani Blumenreich, Tamar Nehushtan, Meital Kupervaser, Tali Shalit, Alexandra Gabashvili, Tammar Joseph, Ivan Milenkovic, John Hardy, Anthony H Futerma. Large-scale proteomics analysis of five brain regions from Parkinson's disease patients with a GBA1 mutation. NPJ Parkinson's disease. vol 10. issue 1. 2024-02-08. PMID:38331996. two proteins were differentially-expressed in all five brain regions whereas significant differences were detected between the brain regions, with changes consistent with loss of dopaminergic signaling in the substantia nigra, and activation of a number of pathways in the cingulate gyrus, including ceramide synthesis. 2024-02-08 2024-02-11 Not clear
Qiuyu Lv, Xuanyi Wang, Pan Lin, Xiang Wan. Neuromelanin-sensitive magnetic resonance imaging in the study of mental disorder: A systematic review. Psychiatry research. Neuroimaging. vol 339. 2024-02-07. PMID:38325165. recent research suggests that neuromelanin-sensitive magnetic resonance imaging (nm-mri) techniques may overcome this limitation by enabling the non-invasive imaging of the substantia nigra (sn)/ ventral tegmental area (vta) dopaminergic and locus coeruleus (lc) noradrenergic systems. 2024-02-07 2024-02-10 Not clear
Larissa Pereira Dantas da Silva, Erika da Cruz Guedes, Isabel Cristina Oliveira Fernandes, Lucas Aleixo Leal Pedroza, Gustavo José da Silva Pereira, Priscila Guber. Exploring Caenorhabditis elegans as Parkinson's Disease Model: Neurotoxins and Genetic Implications. Neurotoxicity research. vol 42. issue 1. 2024-02-06. PMID:38319410. patients with pd have a loss of dopaminergic neurons in the substantia nigra of the basal ganglia, which controls voluntary movements, causing a motor impairment as a result of dopaminergic signaling impairment. 2024-02-06 2024-02-09 human
Rongsha Chen, Ke Li, Yinying Wang, Liyun Song, Ruohua Wang, Wenhui Fan, Ninghui Zhao, Wei Zou, Zhongshan Yang, Jinyuan Ya. Valeric acid reduction by chitosan oligosaccharide induces autophagy in a Parkinson's disease mouse model. Journal of drug targeting. 2024-02-05. PMID:38315456. the present study demonstrated that cos increased dopaminergic neurons in the substantia nigra (sn) and ameliorated dyskinesia in a pd mouse model. 2024-02-05 2024-02-09 mouse
Kei-Ichi Ishikawa, Ayami Okuzumi, Hiroyo Yoshino, Nobutaka Hattori, Wado Akamats. Generation of hiPSCs (JUCGRMi003-A) from a patient with Parkinson's disease with PARK2 mutation. Stem cell research. vol 76. 2024-02-03. PMID:38309147. park2 is the most common autosomal recessive form of parkinson's disease and is caused by mutations in parkin that result in early-onset loss of dopaminergic neurons in the substantia nigra. 2024-02-03 2024-02-06 Not clear
Chong-Lei Fu, Bo-Cheng Dong, Xi Jiang, Dan Li, Jun Ya. A cell therapy approach based on iPSC-derived midbrain organoids for the restoration of motor function in a Parkinson's disease mouse model. Heliyon. vol 10. issue 2. 2024-01-31. PMID:38293351. parkinson's disease (pd) is a neurodegenerative disease characterized by the degeneration of dopaminergic (da) neurons in the substantia nigra and loss of da transmission in the striatum, thus making cell transplantation an effective treatment strategy. 2024-01-31 2024-02-02 mouse
Ana Perez-Villalba, María Salomé Sirerol-Piquer, Raúl Soriano-Cantón, Virginia Folgado, Azucena Pérez-Cañamás, Martina Kirstein, Isabel Fariñas, Francisco Pérez-Sánche. Dopaminergic neuron loss in mice due to increased levels of wild-type human α-Synuclein only takes place under conditions of accelerated aging. Scientific reports. vol 14. issue 1. 2024-01-30. PMID:38291230. these motor disturbances correlate with reduced dopamine (da) levels, increased da turnover, synaptic terminal loss, and notably, the depletion of dopaminergic neurons in the substantia nigra and noradrenergic neurons in the locus coeruleus. 2024-01-30 2024-02-02 mouse
Vasanthi Chinraj, Ramakkamma Aishwarya Reddy, Jubie Selvaraj, Raman Sureshkuma. Design, Synthesis and In Vitro Evaluation of Levodopa Stearic Acid Hydrazide Conjugate for the Management of Parkinson's DiseaseNovel Conjugate for Parkinson's Disease. Drug research. 2024-01-29. PMID:38286420. the pathological identification for parkinson's disease is loss of dopaminergic neurons in substantia nigra region of the brain that in turn leads to dopamine deficiency that affects the body's normal physiological and neurological disorder. 2024-01-29 2024-02-01 Not clear
b' Simone D\'Angiolini, Maria Lui, Emanuela Mazzon, Marco Calabr\\xc3\\xb. Network Analysis Performed on Transcriptomes of Parkinson\'s Disease Patients Reveals Dysfunction in Protein Translation. International journal of molecular sciences. vol 25. issue 2. 2024-01-27. PMID:38279299.' parkinson's disease (pd) is a prevalent neurodegenerative disorder characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra region of the brain. 2024-01-27 2024-01-29 Not clear
Bin Hong, Yosuke Ohtake, Takahide Itokazu, Toshihide Yamashit. Glial senescence enhances α-synuclein pathology owing to its insufficient clearance caused by autophagy dysfunction. Cell death discovery. vol 10. issue 1. 2024-01-25. PMID:38272865. parkinson's disease (pd) is characterized by the pathological accumulation of α-synuclein (α-syn) and loss of dopaminergic neurons in the substantia nigra. 2024-01-25 2024-01-28 mouse